Weiqun Lu1, Zhiliang Huang1, Shicai Chen1, Huizeng Lv2, Xinqi Chen2, Jian Lei3, Chuanfeng Ke3, Chuyuan Hong4, Yisheng Wei4, Rong Su5, Rong Chen5, Zheng Sun6, Ping Yang6, Xiaojun Tan7, Haiying Liu8. 1. Department of Gastrointestinal Surgical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China. 2. Department of General Surgery, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 3. Department of General Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 4. Department of General Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 5. Department of General Surgery, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 6. Department of General Surgery, the First Municipal Hospital of Guangzhou, Guangzhou, China. 7. Department of Pathology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China. 8. Department of Gastrointestinal Surgical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China. gzdlhy@sina.com.
Abstract
BACKGROUND: This study sought to test the effectiveness of EVOSKIN®Palm and sole moisturizing cream (PSMC) in preventing and treating hand-foot syndrome (HFS) during capecitabine chemotherapy. METHODS:Stage II/III colorectal cancer patients receivingcapecitabine adjuvant chemotherapy were randomly allocated to receive either EVOSKINPSMC or physiological saline treatments for their hands and feet. Treatment was initiated along with adjuvant chemotherapy and continued till the end of chemotherapy. Participants' skin responses were evaluated every 3 weeks. RESULTS: During the study, 51 participants in the EVOSKIN PSMC group and 54 participants in thephysiological saline group completed at least three cycles of capecitabine chemotherapy. The total incidence of HFS in the EVOSKIN PSMC group was lower than that in the physiological saline group (56.8% vs. 75.9%, P=0.006), as was the incidence of Grade 3/4 HFS (6.0% vs. 18.5%, P=0.011). The incidence of HFS became significant after 6weeks of chemotherapy. Further, the incidence of severe HFS was significant from as early as 3weeks after the commencement of chemotherapy despite the use of EVOSKIN PSMC to manage the condition. Notably, the incidence of Grade 1/2 HFS was not statistically significant between the two groups (26/51 vs. 32/54, 52.0% vs. 59.2%, P=0.194). CONCLUSIONS: The incidence of severe HFS among individuals using oral capecitabine can be reduced by the prophylactic treatment of EVOSKIN PSMC, this treatment is reasonable and acceptable for patients with capecitabine chemotherapy.
RCT Entities:
BACKGROUND: This study sought to test the effectiveness of EVOSKIN®Palm and sole moisturizing cream (PSMC) in preventing and treating hand-foot syndrome (HFS) during capecitabine chemotherapy. METHODS: Stage II/III colorectal cancerpatients receiving capecitabine adjuvant chemotherapy were randomly allocated to receive either EVOSKINPSMC or physiological saline treatments for their hands and feet. Treatment was initiated along with adjuvant chemotherapy and continued till the end of chemotherapy. Participants' skin responses were evaluated every 3 weeks. RESULTS: During the study, 51 participants in the EVOSKIN PSMC group and 54 participants in the physiological saline group completed at least three cycles of capecitabine chemotherapy. The total incidence of HFS in the EVOSKIN PSMC group was lower than that in the physiological saline group (56.8% vs. 75.9%, P=0.006), as was the incidence of Grade 3/4 HFS (6.0% vs. 18.5%, P=0.011). The incidence of HFS became significant after 6weeks of chemotherapy. Further, the incidence of severe HFS was significant from as early as 3weeks after the commencement of chemotherapy despite the use of EVOSKIN PSMC to manage the condition. Notably, the incidence of Grade 1/2 HFS was not statistically significant between the two groups (26/51 vs. 32/54, 52.0% vs. 59.2%, P=0.194). CONCLUSIONS: The incidence of severe HFS among individuals using oral capecitabine can be reduced by the prophylactic treatment of EVOSKIN PSMC, this treatment is reasonable and acceptable for patients with capecitabine chemotherapy.